Journal of Alzheimer's Disease · Nov 21, 2026
Serum fibroblast growth factor-23 and risk of incident stroke and dementia: The Atherosclerosis Risk in Communities Study
By Lutsey PL, Sauerer DM, Michos ED et al.
Background: Elevated concentrations of fibroblast growth factor 23 (FGF23), a hormone involved in bone mineral and vitamin D metabolism, may be associated with risk of stroke and dementia through inflammation, endothelial dysfunction, vessel calcification and stiffness, and axonal degeneration. Objective: We tested the hypothesis that elevated FGF23 is associated with increased risk of dementia and stroke. Methods: FGF23 was measured in serum samples collected in 1990–1992 from 12,391 participants of the Atherosclerosis Risk in Communities study. Participants were followed through 2019 for incident stroke and dementia. Cox regression was used to examine the associations of FGF23 (in quintiles) with risk of stroke and dementia, with adjustment for demographics, cardiovascular and dementia risk factors, and kidney function. Results: Participants (mean 56.9 years; 57% female) were followed a median of 24 years; 1183 developed stroke and 2402 developed dementia. Participants in the highest versus lowest quintile of serum FGF23 were at elevated risk of stroke [HR (95% CI): 1.27 (1.06–1.51)] and dementia [HR: 1.21 (1.06–1.38)] independent of baseline demographics. Associations attenuated with additional adjustment for traditional cardiovascular risk factors [HR stroke : 1.20 (1.00–1.45); HR dementia : 1.17 (1.03–1.35)], and became even weaker after accounting for eGFR [HR stroke : 1.13 (0.94–1.37); HR dementia : 1.14 (1.00–1.31)]. The associations of FGF23 with incident stroke and dementia were not modified by categories of age, sex, race, or eGFR. Conclusions: Higher FGF23 was associated with modestly greater risk of stroke and dementia in this population-based sample, though the association was largely attenuated after adjustment for traditional cardiovascular risk factors and kidney function.